2020

1. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

   Cancers, Vol. 12, Núm. 12, pp. 1-27

2. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

   Cells, Vol. 9, Núm. 10